Improving Long-Acting Injectable HIV Prevention in Clinics
Part of Immune system & allergy, Infections clinical trials.
This study helps healthcare providers and clinics deliver long-acting injectable PrEP (a preventive HIV medication given as an injection) more effectively. Researchers will study how clinics can better implement and offer this option to patients who need it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthcare provider, staff member, or clinic worker involved in prescribing or supporting PrEP care
- You are 18 years of age or older
- You work at a clinic participating in this study
- OR: You are a patient aged 16 or older who had a PrEP-related clinic visit during the study period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This trial tests a “one-stop” support pathway meant to make it easier for PrEP clinics in Kenya to deliver PrEP care. It involves interviews with people using PrEP services and with healthcare and policy leaders who help run or guide PrEP delivery.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This trial tests a nurse-run program that makes it easier to get long-acting injectable PrEP (cabotegravir) for HIV prevention. It aims to see if nurses can start and provide this shot quickly at your regular clinic visits.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.